Cipla Reports Q2: 4% YoY Net Profit Rise to Rs 1,351 Crore, 8% Revenue Growth

Pharma giant Cipla recently announced a 4% increase in its consolidated net profit year-on-year, reaching Rs 1,351 crore. Revenue from operations also saw an uptick of 8% year-on-year, totaling Rs 7,589 crore.

In the second quarter, EBITDA improved slightly by 0.5% year-on-year, landing at Rs 1,895 crore, with a margin of 25%.

Segment Performance

In terms of segments, Cipla’s India business generated Rs 3,146 crore, reflecting a 7% growth year-on-year. Notably, the company’s brand Foracort holds the top rank in the domestic market. On the other hand, the North America business logged revenues of $233 million, with Albuterol maintaining its leadership in the U.S. Albuterol MDI market, commanding a 22% share.

Cipla’s North America operations continued to show significant traction with key differentiated assets in Q2 FY26. The Lanreotide product also gained market share, climbing to 22% during the quarter.

Additionally, Cipla expanded its U.S. portfolio by launching Filgrastim, marking its first biosimilar in the American market. Also noteworthy is the classification of Cipla’s manufacturing facility in Bommasandra, Bengaluru, as VAI (Voluntary Action Indicated) by the U.S. FDA, which is a favorable regulatory achievement supporting its U.S. operations.

Future Outlook

Looking toward the future, Cipla plans to introduce four significant respiratory assets by calendar year 2026, including gAdvair in Q4 FY26. This pipeline also includes three peptide assets like Liraglutide. Importantly, three of these four respiratory products will be filed from Cipla’s U.S. manufacturing sites, which mitigates regulatory risks and boosts supply reliability. The Africa segment recorded revenues of $134 million, a 5% increase year-on-year, while Cipla’s South Africa private market business grew at an impressive rate of 1.3 times the market average. The Emerging Markets and Europe sector also reported $110 million in revenue, showcasing a 15% year-on-year growth and achieving its highest quarterly revenue to date in this region. In branded prescriptions, Cipla retained its second position in the overall chronic segment, with a chronic mix improved to 61.8%. Major therapy areas including urology, anti-diabetics, cardiac, anti-infectives, and dermatology outperformed market growth.

The trade generics division experienced notable growth driven by a broader product offering. Currently, Cipla boasts two brands with trailing twelve-month (TTM) revenues exceeding Rs 100 crore, along with five brands generating TTM revenue between Rs 50 crore and Rs 100 crore. In Q2 FY26, the company launched six new products, marking its entry into the orthocare category to broaden therapeutic coverage.

In the consumer health sector, Cipla achieved robust growth, with anchor and transitioned brands performing well. The business continued its upward trajectory in EBITDA, with flagship products Nicotex, Omnigel, and Cipladine maintaining their No. 1 status in their respective categories.

On Thursday, Cipla shares were trading slightly higher at Rs 1,582 on the NSE.